Monoklonalne przeciwciała w szpiczaku plazmocytowym – przełom w terapii

Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due to new drugs introduction, overall survival of the patients has improved very much. Nevertheless new active ingredients are being searched. There is growing attention to monoclonal antibodies. Over 20 molecules are being investigated, but none of them has already been approved in MM. Work on elotuzumab, daratumumab and in bone disease on denosumab is the most advanced. In this article we describe the current state of knowledge.